TSX runs higher on rate cut expectations
Investing.com -- Haleon (LON:HLN) (NYSE:HLN) shares slipped on Thursday after the company lowered its full-year organic revenue growth forecast, flagging weaker performance in North America that weighed on first-half results.
The stock was down 1.4% in London trading as of 10:04 GMT.
The maker of Sensodyne and Panadol now expects organic revenue growth of around 3.5% for 2025, down from its previous 4% to 6% range. That range will instead apply to guidance starting in 2026, alongside a new target for high-single-digit adjusted operating profit growth at constant currency.
For 2025, Haleon is also targeting high-single-digit organic operating profit growth.
Total (EPA:TTEF) revenue for the six months ended June declined 3.8% to £5.48 billion, primarily due to soft demand in North America, where the company cited a challenging consumer environment and retailer destocking. In contrast, sales rose in EMEA and Asia-Pacific.
On an organic basis, first-half revenue rose 3.2% year-over-year, slightly below the 3.4% growth expected by analysts.
"This is a weak update," Jefferies analysts said in a note. "The organic sales growth guide cut is more extreme than feared."
Adjusted operating profit for the first six months rose 9.9% to £1.24 billion, narrowly beating expectations.
Adjusted pretax profit came in at £1.11 billion.